/GNFT
GNFT Stock - Genfit S.A.
Healthcare|BiotechnologyNASDAQ
$5.61-0.18%
$0.01 (-0.18%) • Dec 18
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+131.7%upside
Target: $13.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GNFT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.55 – $5.67
TARGET (TP)$13.00
STOP LOSS$5.16
RISK/REWARD1:16.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.87
52W High$5.86
52W Low$2.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $67.00M | $28.57M | $20.20M | $80.07M | $765,000 |
| Gross Profit | $66.70M | $28.22M | $19.95M | $79.91M | $563,000 |
| Gross Margin | 99.6% | 98.8% | 98.8% | 99.8% | 73.6% |
| Operating Income | $3.28M | $-26,580,000 | $-27,289,000 | $31.82M | $-82,897,000 |
| Net Income | $1.51M | $-28,894,000 | $-23,720,000 | $67.26M | $-101,221,000 |
| Net Margin | 2.2% | -101.2% | -117.5% | 84.0% | -13231.5% |
| EPS | $0.03 | $-0.58 | $-0.48 | $1.50 | $-2.60 |
Company Overview
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 60.4% Upside
Now
$9
Low
$9
Average
$9
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 19th 2025 | H.C. Wainwright | Resumed | Buy | $9 |
Earnings History & Surprises
GNFTBeat Rate
44%
Last 9 quarters
Avg Surprise
+18.3%
EPS vs Estimate
Beats / Misses
4/5
Last 12 quarters
Latest EPS
$-0.24
Q3 2025
EPS Surprise History
Q3 22
+71.0%
$-0.21vs$-0.71
Q4 22
No data
Q3 23
No data
Q3 23
-41.1%
$-0.45vs$-0.32
Q4 23
No data
Q3 24
+62.3%
$0.54vs$0.33
Q2 25
-148.9%
$-0.64vs$-0.26
Q3 25
-119.8%
$-0.24vs$1.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q3 2025 | Sep 22, 2025 | $1.19 | $-0.24 | -119.8% | ✗ MISS |
Q2 2025 | May 22, 2025 | $-0.26 | $-0.64 | -148.9% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | — | — | — | — |
Q3 2024 | Sep 19, 2024 | $0.33 | $0.54 | +62.3% | ✓ BEAT |
Q4 2023 | Dec 30, 2023 | — | $-0.18 | — | — |
Q3 2023 | Sep 20, 2023 | $-0.32 | $-0.45 | -41.1% | ✗ MISS |
Q3 2023 | Jul 13, 2023 | — | $-0.46 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.29 | — | — |
Q3 2022 | Sep 28, 2022 | $-0.71 | $-0.21 | +71.0% | ✓ BEAT |
Q2 2022 | Apr 7, 2022 | $-0.92 | $1.40 | +252.9% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $1.16 | — | — |
Q3 2021 | Sep 29, 2021 | $-1.22 | $0.22 | +118.1% | ✓ BEAT |
Q2 2021 | Apr 1, 2021 | $-1.28 | $-1.46 | -13.7% | ✗ MISS |
Q3 2020 | Sep 30, 2020 | $-1.37 | $-1.60 | -16.3% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | — | $-0.41 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-1.86 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.49 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-1.64 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-1.37 | — | — |
Latest News
GENFIT 9-Months 2025 Revenue €39.2 Million; Says As of September 30, 2025, The Company's Cash And Cash Equivalents Amounted To €119.0 Million Compared With €107.5 Million As Of June 30, 2025, And €81.8 Million As Of December 31, 2024
📈 PositiveBenzinga•Nov 20, 2025, 05:13 PM
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
📈 PositiveSeeking Alpha•Oct 9, 2025, 03:33 PM•Also: , ,
HC Wainwright & Co. Maintains Buy on Genfit, Lowers Price Target to $7
➖ NeutralBenzinga•Sep 24, 2025, 11:01 AM
GENFIT shares are trading lower after the company reported a year-over-year decrease in H1 financial results.
📉 NegativeBenzinga•Sep 23, 2025, 05:58 PM
Genfit H1 EPS $(0.23) Down From $0.57 YoY, Sales $40.443M Down From $65.887M YoY
📉 NegativeBenzinga•Sep 22, 2025, 08:11 PM
Genfit Announces Discontinuation Of Its VS-01 Program In ACLF: VS-01 Development Refocused On UCD; Says Following Discontinuation Of Our VS-01 Program In ACLF, We Anticipate A Substantial Reduction In Our Operating Expenses
📉 NegativeBenzinga•Sep 19, 2025, 08:17 PM
HC Wainwright & Co. Assumes Genfit at Buy, Announces Price Target of $9
📈 PositiveBenzinga•Aug 19, 2025, 11:13 AM
Frequently Asked Questions about GNFT
What is GNFT's current stock price?
Genfit S.A. (GNFT) is currently trading at $5.61 per share. The stock has moved -0.18% today.
What is the analyst price target for GNFT?
The average analyst price target for GNFT is $13.00, based on 1 analyst.
What sector is Genfit S.A. in?
Genfit S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GNFT's market cap?
Genfit S.A. has a market capitalization of $0.28 billion, making it a small-cap company.
Does GNFT pay dividends?
No, Genfit S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.2B
EPRX
Eupraxia Pharmaceuticals Inc.
$6.56
Mkt Cap: $0.2B
IVA
Inventiva S.A.
$4.21
Mkt Cap: $0.2B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
MDWD
MediWound Ltd.
$18.77
Mkt Cap: $0.2B
NTHI
Neonc Technologies Holdings, Inc.
$7.01
Mkt Cap: $0.1B
OBIO
Orchestra BioMed Holdings, Inc.
$4.35
Mkt Cap: $0.2B
PRLD
Prelude Therapeutics Incorporated
$2.14
Mkt Cap: $0.2B
SLS
SELLAS Life Sciences Group, Inc.
$2.36
Mkt Cap: $0.2B
TARA
Protara Therapeutics, Inc.
$5.27
Mkt Cap: $0.2B
Explore stocks similar to GNFT for comparison